Purpose Oligometastatic non–small cell lung cancer (NSCLC) patients have been increasingly regarded as a distinct group that could benefit from local treatment to achieve a better clinical outcome. However, current definitions of oligometastasis are solely numerical, which are imprecise because of ignoring the biological heterogeneity caused by genomic characteristics. Our study aimed to profile the molecular alterations of oligometastatic NSCLC and elucidate its potential difference from polymetastasis.
Materials and Methods We performed next-generation sequencing to analyze tumors and paired peripheral blood from 77 oligometastatic and 21 polymetastatic NSCLC patients to reveal their genomic characteristics and assess the genetic heterogeneity.
Results We found ERBB2, ALK, MLL4, PIK3CB, and TOP2A were mutated at a significantly lower frequency in oligometastasis compared with polymetastasis. EGFR and KEAP1 alterations were mutually exclusive in oligometastatic group. More importantly, oligometastasis has a unique significant enrichment of apoptosis signaling pathway. In contrast to polymetastasis, a highly enriched COSMIC signature 4 and a special mutational process, COSMIC signature 14, were observed in the oligometastatic cohort. According to OncoKB database, 74.03% of oligometastatic NSCLC patients harbored at least one actionable alteration. The median tumor mutation burden of oligometastasis was 5.00 mutations/Mb, which was significantly associated with smoking, DNA damage repair genes, TP53 mutation, SMARCA4 mutation, LRP1B mutation, ABL1 mutation.
Conclusion Our results shall help redefine oligometastasis beyond simple lesion enumeration that will ultimately improve the selection of patients with real oligometastatic state and optimize personalized cancer therapy for oligometastatic NSCLC.
Citations
Citations to this article as recorded by
Prognostic and Predictive Biomarkers of Oligometastatic NSCLC: New Insights and Clinical Applications Mandy Jongbloed, Martina Bortolot, Leonard Wee, Jarno W.J. Huijs, Murillo Bellezo, Rianne D.W. Vaes, Frank Aboubakar Nana, Koen J. Hartemink, Dirk K.M. De Ruysscher, Lizza E.L. Hendriks JTO Clinical and Research Reports.2024; 5(12): 100740. CrossRef
Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma Guangming Yi, Fanghao Cai, Liangzhong Liu, Rongxin Liao, Xuan Jiang, Zhenzhou Yang, Xiaoyue Zhang Future Oncology.2024; 20(40): 3477. CrossRef
Purpose The occurrence pattern of immune-related adverse events (irAEs) induced by immune checkpoint inhibitor (ICI) in cancer treatment remains unclear.
Materials and Methods Phase II-III clinical trials that evaluated ICI-based treatments in cancer and were published between January 2007 and December 2019 were retrieved from public electronic databases. The pooled median time to onset (PMT-O), resolution (PMT-R), and immune-modulation resolution (PMT-IMR) of irAEs were generated using the metamedian package of R software.
Results Twenty-two eligible studies involving 23 clinical trials and 8,436 patients were included. The PMT-O of all-grade irAEs ranged from 2.2 to 14.8 weeks, with the longest in renal events. The PMT-O of grade ≥ 3 irAEs was significantly longer than that of all-grade irAEs induced by programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) inhibitors (27.5 weeks vs. 8.4 weeks, p < 0.001) and treatment of nivolumab (NIV) plus ipilimumab (IPI) (7.9 weeks vs. 6.0 weeks, p < 0.001). The PMT-R of all-grade irAEs ranged from 0.1 to 54.3 weeks, with the shortest and longest in hypersensitivity/infusion reaction and endocrine events, respectively. The PMT-IMR of grade ≥ 3 irAEs was significantly shorter than that of all-grade irAEs caused by PD-1/PD-L1 blockade (6.9 weeks vs. 40.6 weeks, p=0.002) and NIV+IPI treatment (3.1 weeks vs. 5.9 weeks, p=0.031).
Conclusion This study revealed the general and specific occurrence pattern of ICI-induced irAEs in pan-cancers, which was deemed to aid the comprehensive understanding, timely detection, and effective management of ICI-induced irAEs.
Citations
Citations to this article as recorded by
Oral and cutaneous immune‐related adverse events in cancer patients: Prevalence and overall survival Osias Vieira de Oliveira Filho, Ivana Lameiras Gibbons, Yuri de Lima Medeiros, Thiago Bueno de Oliveira, Nathaniel Simon Treister, Fabio Abreu Alves Oral Diseases.2025; 31(1): 278. CrossRef
Association between immune checkpoint inhibitor and cytomegalovirus infection: A pharmacovigilance study based on the adverse event reporting system Naoto Okada, Tomoyuki Yanagi, Takaaki Sasaki, Miho Tamura, Masakazu Ozaki, Atsuyuki Saisyo, Takashi Kitahara International Journal of Cancer.2025; 156(2): 293. CrossRef
A Case of Olmesartan-associated Gastritis Observed Over Time Mizuho Fujisawa, Tetsuya Yoshizaki, Satoshi Urakami, Risa Ashizaki, Eri Nishikawa, Hiroshi Tanabe, Shinya Hoki, Ryosuke Ishida, Hitomi Hori, Chise Ueda, Hirofumi Abe, Madoka Takao, Yoshinori Morita, Takashi Toyonaga, Yuzo Kodama Internal Medicine.2025;[Epub] CrossRef
The use of peripheral blood biomarkers for predicting the risk of immune-related adverse events in immune checkpoint inhibitor therapy Louise E Duvall Annals of Clinical Biochemistry: International Journal of Laboratory Medicine.2025;[Epub] CrossRef
Developing alert thresholds and self-management advice for people receiving immune checkpoint inhibitors: a Multinational Association for Supportive Care in Cancer modified Delphi survey Julia Lai-Kwon, Claudia Rutherford, Stephanie Best, Hope S. Rugo, Christina H. Ruhlmann, Michael Jefford Supportive Care in Cancer.2025;[Epub] CrossRef
Very Early Health Technology Assessment for Potential Predictive Biomarkers in the Treatment of Advanced Non-Small Cell Lung Cancer Leila-Sophie Otten, Alessandra I. G. Buma, Berber Piet, Rob ter Heine, Michel M. van den Heuvel, Valesca P. Retèl PharmacoEconomics - Open.2025;[Epub] CrossRef
Clinical and economic impact of the advanced practice nurse in lung cancer patients receiving immunotherapy-based treatments: A quantitative study Jorgina Serra-López, Clara Pujol-Besora, Sergio Martínez-Recio, Andrés Barba Joaquín, Mariona Riudavets Melià, Ivana Sullivan, Jordi Torralbas-Ortega, Gina Lladó-Jordan, Margarita Majem, Maria-Antonia Martínez-Momblan European Journal of Oncology Nursing.2025; 74: 102809. CrossRef
Long-term immune related adverse events Leo Plaçais, Olivier Lambotte Current Opinion in Oncology.2025; 37(2): 142. CrossRef
Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the ICOG Study Jonas Paul Wiegmann, Tabea Fröhlich, Nora Möhn, Laura Duzzi, Emily Narten, Johanna Aurich, Janin Thomas, Lea Grote‐Levi, Susann Mahjoub, Dominik Berliner, Thomas Wirth, Heiko Golpon, Benjamin‐Alexander Bollmann, Imke Von Wasilewski, Ralf Gutzmer, Florian Cancer Medicine.2025;[Epub] CrossRef
Application of Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma: Current Status, Challenges, and Future Directions Lingxiang Ran, Rui Zhao, Yu Li, Benfan Lin, Zhen Yang, Yuanyin Teng, Jingyi Li, Shi Wang, Hsu Yi Liang, Guangmo Hu AI Med.2025; 1(1): 1. CrossRef
Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients Ting Yan, Minghui Long, Chaoyi Liu, Jiwen Zhang, Xingyu Wei, Fei Li, Dehua Liao Frontiers in Pharmacology.2025;[Epub] CrossRef
Immune checkpoint inhibitor–related adverse events: Real-world experience from a single veterans’ affairs medical center Samantha Benz, Katherine A Sherman, Constantin A Dasanu, Juliana Alvarez-Argote Journal of Oncology Pharmacy Practice.2024; 30(4): 697. CrossRef
Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune Checkpoint Inhibitors Kremena Petrova Trichkova, Franziska Görtler, Line Bjørge, Cornelia Schuster Cancers.2024; 16(2): 250. CrossRef
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU Mar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Gastroenterología y Hepatología.2024; 47(4): 401. CrossRef
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU Mar Riveiro-Barciela, Sabela carballal, Álvaro Díaz-González, Miriam Mañosa, Javier Gallgo-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandí Revista Española de Enfermedades Digestivas.2024;[Epub] CrossRef
Discontinuation risk from adverse events: immunotherapy alone vs. combined with chemotherapy: a systematic review and network meta-analysis Sangwon Shin, Jimin Moon, Chiyoon Oum, Seulki Kim, Soo Ick Cho, Yoojoo Lim, Chan-Young Ock, Seunghwan Shin BMC Cancer.2024;[Epub] CrossRef
A case of Stiff-person syndrome with muscle tonicity of the extremities and neck after use of Dulvalumab for lung adenocarcinoma Takashi Inoue, Kei Oiwa, Kazuhiro Horiuchi Rinsho Shinkeigaku.2024; 64(3): 176. CrossRef
Clinical and translational attributes of immune-related adverse events Karijn P. M. Suijkerbuijk, Mick J. M. van Eijs, Femke van Wijk, Alexander M. M. Eggermont Nature Cancer.2024; 5(4): 557. CrossRef
Immune checkpoint inhibitors and neurotoxicity: a focus on diagnosis and management for a multidisciplinary approach Desirèe Speranza, Mariacarmela Santarpia, Francesco Luppino, Fausto Omero, Enrica Maiorana, Mariacarmela Cavaleri, Elena Sapuppo, Vincenzo Cianci, Alessia Pugliese, Vito Racanelli, Giulia Maria Camerino, Carmelo Rodolico, Nicola Silvestris Expert Opinion on Drug Safety.2024; 23(11): 1405. CrossRef
Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation Arielle Elkrief, Nicholas R. Waters, Natalie Smith, Angel Dai, John Slingerland, Nathan Aleynick, Binita Febles, Pooja Gogia, Nicholas D. Socci, Melissa Lumish, Paul A. Giardina, Jamie E. Chaft, Juliana Eng, Robert J. Motzer, Robin B. Mendelsohn, Kate A. Cancer Immunology Research.2024; 12(3): 308. CrossRef
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU Mar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Gastroenterología y Hepatología (English Edition).2024; 47(4): 401. CrossRef
Pathogenesis, Diagnosis and Treatment of Immune-Related Cardiotoxicity 静宜 任 Advances in Clinical Medicine.2024; 14(03): 284. CrossRef
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients Alicja Puszkiel, Guillaume Bianconi, Blaise Pasquiers, David Balakirouchenane, Jennifer Arrondeau, Pascaline Boudou-Rouquette, Marie-Claire Bretagne, Joe-Elie Salem, Xavier Declèves, Michel Vidal, Nora Kramkimel, Sarah Guegan, Selim Aractingi, Olivier Hui British Journal of Cancer.2024; 130(11): 1866. CrossRef
Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian S Maria Chiara Zatelli, Antongiulio Faggiano, Antonella Argentiero, Romano Danesi, Stella D'Oronzo, Stefano Fogli, Tindara Franchina, Francesco Giorgino, Nicola Marrano, Dario Giuffrida, Stefania Gori, Giampiero Marino, Rossella Mazzilli, Matteo Monami, Mon Cancer Treatment Reviews.2024; 126: 102734. CrossRef
Tumor-Agnostic Therapy—The Final Step Forward in the Cure for Human Neoplasms? Mohamed Mahmoud El-Sayed, Julia Raffaella Bianco, YiJing Li, Zsolt Fabian Cells.2024; 13(12): 1071. CrossRef
Mesenteric Panniculitis as a Side Effect of Nivolumab in a Patient with Larnyngeal Cancer O Karhan, Y Sezgin, S Ileri, S Tunc Nigerian Journal of Clinical Practice.2024; 27(6): 800. CrossRef
Real‐world first‐line treatment with pembrolizumab for non‐small cell lung carcinoma with high PD‐L1 expression: Updated analysis Yasuyuki Ikezawa, Ryo Morita, Hidenori Mizugaki, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Furuta Megumi, Hisashi Tanaka, Motoki Sekikawa, T Cancer Medicine.2024;[Epub] CrossRef
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study Guihong Wan, Wenxin Chen, Sara Khattab, Katie Roster, Nga Nguyen, Boshen Yan, Ahmad Rajeh, Jayhyun Seo, Hannah Rashdan, Leyre Zubiri, Matthew J Hadfield, Shadmehr Demehri, Kun-Hsing Yu, William Lotter, Alexander Gusev, Nicole R LeBoeuf, Kerry L Reynolds, The Lancet Oncology.2024; 25(8): 1053. CrossRef
Selecting Immune Checkpoint Inhibitor Side Effects for Real-Time Monitoring in Routine Cancer Care: A Modified Delphi Study Julia Lai-Kwon, Michael Jefford, Stephanie Best, Iris Zhang, Claudia Rutherford JCO Oncology Practice.2024; 20(12): 1663. CrossRef
Differences in checkpoint-inhibitor-induced hypophysitis: mono- versus combination therapy induced hypophysitis Stephanie van der Leij, Karijn P.M. Suijkerbuijk, Medard F.M. van den Broek, Gerlof D. Valk, Jan Willem Dankbaar, Hanneke M. van Santen Frontiers in Endocrinology.2024;[Epub] CrossRef
Unravelling the Acute, Chronic and Steroid-Refractory Management of High-Grade Neurological Immune-Related Adverse Events: A Call to Action Antonio Malvaso, Pierpaolo Giglio, Luca Diamanti, Matteo Gastaldi, Elisa Vegezzi, Andrea Pace, Paola Bini, Enrico Marchioni Brain Sciences.2024; 14(8): 764. CrossRef
Machine learning modeling of patient health signals informs long-term survival on immune checkpoint inhibitor therapy Gerald J. Sun, Gustavo Arango-Argoty, Gary J. Doherty, Damian E. Bikiel, Dejan Pavlovic, Allen C. Chen, Ross A. Stewart, Zhongwu Lai, Etai Jacob iScience.2024; 27(9): 110634. CrossRef
Clinical Outcomes of Elective Early Discontinuation of Immunotherapy Based on Objective Response in Microsatellite Instability-High Metastatic Colorectal Cancer Annie Xiao, Xiaochen Li, Chongkai Wang, Marwan Fakih Clinical Colorectal Cancer.2024;[Epub] CrossRef
Toxicity in the era of immune checkpoint inhibitor therapy Synat Keam, Naimah Turner, Fernanda G. Kugeratski, Rene Rico, Jocelynn Colunga-Minutti, Rayansh Poojary, Sayan Alekseev, Anisha B. Patel, Yuanteng Jeff Li, Ajay Sheshadri, Monica E. Loghin, Karin Woodman, Ashley E. Aaroe, Sarah Hamidi, Priyanka Chandrasek Frontiers in Immunology.2024;[Epub] CrossRef
Onco-Primary Care of Patients Receiving Immune Checkpoint Inhibitors Christopher J. Hoimes, Suzanne McGettigan, Lee Schwartzberg The American Journal of Medicine.2024; 137(12): 1200. CrossRef
Subjective symptoms are triggers for the detection of immune checkpoint inhibitor-induced interstitial lung disease and associate with disease severity: a single-center retrospective study Mari Yokoi, Atsushi Yonezawa, Daiki Hira, Tomohiro Handa, Kiminobu Tanizawa, Shunsaku Nakagawa, Masahiro Tsuda, Yasuaki Ikemi, Ryo Itotani, Hironori Yoshida, Motoo Nomura, Junichi Matsubara, Kosaku Murakami, Hiroaki Ozasa, Manabu Muto, Tomohiro Terada Journal of Pharmaceutical Health Care and Sciences.2024;[Epub] CrossRef
Melittin-incorporated nanomedicines for enhanced cancer immunotherapy Xuefeng Duan, Haoyang Zou, Jiazhen Yang, Shixian Liu, Tianmin Xu, Jianxun Ding Journal of Controlled Release.2024; 375: 285. CrossRef
Do corticosteroids affect immunotherapy efficacy in malignancy? – A systematic review Yoni Byron, Sonya Yegorova‐Lee, Martin Tio Cancer Medicine.2024;[Epub] CrossRef
Immune Checkpoint Inhibitors in the Pre-Transplant Hepatocellular Carcinoma Setting: A Glimpse Beyond the Liver Luca Marzi, Andrea Mega, Chiara Turri, Stefano Gitto, Federica Ferro, Gilbert Spizzo International Journal of Molecular Sciences.2024; 25(21): 11676. CrossRef
Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy Iris Teruel, Eva Castellà, Sabela Recalde, Gemma Viñas, Anna Petit, Macedonia Trigueros, Eva Martínez-Balibrea, Eudald Felip, Milana Bergamino, Adrià Bernat-Peguera, Beatriz Cirauqui, Vanesa Quiroga, Angelica Ferrando-Díez, Anna Pous, Assumpció López, Lai International Journal of Molecular Sciences.2024; 25(22): 12241. CrossRef
Real world comparison of immune-related adverse events with nivolumab-relatlimab versus ipilimumab-nivolumab in patients with advanced cutaneous melanoma Brooke Kielkowski, Diana Mansour, Brooke Ebbert, Kelsea Seago, Sijin Wen, Hang Li, Christine Barrett Journal of Oncology Pharmacy Practice.2024;[Epub] CrossRef
Association of Immune-Related Adverse Events With Efficacy in Consolidation Nivolumab Plus Ipilimumab or Nivolumab Alone After Chemoradiation in Patients With Unresectable Stage III Nonsmall Cell Lung Cancer: An Exploratory Analysis From the Big 10 Cancer Cynthia X. Wei, Sandra K. Althouse, Hirva Mamdani, Nasser H. Hanna, Greg A. Durm Clinical Lung Cancer.2024;[Epub] CrossRef
Safety of sequential immune checkpoint inhibitors after prior immune therapy Muhammad Awidi, Brendan Connell, Delaney Johnson, Isabel Craven, Rojer Ranjit, Brigitte Gil, Natalie Dal’Bo, Lewena Maher, Seanna Reilly Daves, Stephanie McDonald, Krishna S. Gunturu Journal of Cancer Research and Clinical Oncology.2023; 149(6): 2375. CrossRef
The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex Murielle N. Wahli, Stefanie Hayoz, Dennis Hoch, Christoph O. Ryser, Michèle Hoffmann, Amina Scherz, Birgit Schwacha-Eipper, Simon Häfliger, Julian Wampfler, Martin D. Berger, Urban Novak, Berna C. Özdemir Journal of Cancer Research and Clinical Oncology.2023; 149(7): 3847. CrossRef
Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy Atsushi Yamaguchi, Yoshitaka Saito, Katsuya Narumi, Ayako Furugen, Yoh Takekuma, Naofumi Shinagawa, Yasushi Shimizu, Hirotoshi Dosaka-Akita, Mitsuru Sugawara, Masaki Kobayashi Journal of Cancer Research and Clinical Oncology.2023; 149(4): 1659. CrossRef
Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large‐scale pharmacovigilance analysis Qian Guo, Jian Gao, Hui Guo, Jun Xie, Jingmin Cheng International Immunopharmacology.2023; 114: 109490. CrossRef
Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis Su Jeong Song, Yun-Kyoung Song, Mihwa Jang, Eunjeong Shin, Sung Yun Suh, Yoon Sook Cho, Ju-Yeun Lee, Jung Mi Oh Targeted Oncology.2023; 18(1): 147. CrossRef
Immune checkpoint inhibitor-induced aplastic anaemia: Case series and large-scale pharmacovigilance analysis Qian Guo, Jin Ning Zhao, Ting Liu, Jian Gao, Hui Guo, Jing Min Cheng Frontiers in Pharmacology.2023;[Epub] CrossRef
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Makoto Nishio, Tony S. K. Mok, Martin Reck, Gene G. Finley, Monika D. Kaul, Wei Yu, Nindhana Paranthaman, Ilze Bāra, Howard J. West JAMA Oncology.2023; 9(4): 527. CrossRef
Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment Gaetano Maria Russo, Anna Russo, Fabrizio Urraro, Fabrizio Cioce, Luigi Gallo, Maria Paola Belfiore, Angelo Sangiovanni, Stefania Napolitano, Teresa Troiani, Pasquale Verolino, Antonello Sica, Gabriella Brancaccio, Giulia Briatico, Valerio Nardone, Alfons Diagnostics.2023; 13(4): 793. CrossRef
Blood cell counts can predict adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis Juyue Zhou, Zhonghai Du, Jie Fu, Xiuxiu Yi Frontiers in Immunology.2023;[Epub] CrossRef
Gastritis as an immunotherapy-related toxicity in the treatment of endometrial cancer: A case report Nidhi Goel, Monica D. Levine, Laura M. Chambers, Christa I. Nagel Gynecologic Oncology Reports.2023; 47: 101174. CrossRef
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology Jarushka Naidoo, Catherine Murphy, Michael B Atkins, Julie R Brahmer, Stephane Champiat, David Feltquate, Lee M Krug, Javid Moslehi, M Catherine Pietanza, Joanne Riemer, Caroline Robert, Elad Sharon, Maria E Suarez-Almazor, Karthik Suresh, Michelle Turner Journal for ImmunoTherapy of Cancer.2023; 11(3): e006398. CrossRef
Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients Berna C. Özdemir, Cristina Espinosa da Silva, Dimitri Arangalage, Pierre Monney, Sabina A. Guler, Uyen Huynh-Do, Guido Stirnimann, Lucia Possamai, Roman Trepp, Robert Hoepner, Anke Salmen, Camille L. Gerard, Petr Hruz, Lisa Christ, Sacha I. Rothschild Cancer Immunology, Immunotherapy.2023; 72(7): 1991. CrossRef
Immune checkpoint inhibitor-induced cutaneous toxicities: a review of histopathologic and clinical features Julianna Martel, Hannah L. Hanania, Anisha B. Patel Human Pathology.2023; 140: 144. CrossRef
Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity Catherine C. Fahey, Thomas J. Gracie, Douglas B. Johnson Expert Review of Anticancer Therapy.2023; 23(7): 673. CrossRef
Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment Rafael Morales-Barrera, Guillermo Villacampa, Natalia Vidal, Mariona Figols, Julia Giner, Teresa Bonfill, Cristina Suárez, Nely Díaz, Joaquín Mateo, Macarena González, Montserrat Domenech, Javier Puente, Joan Carles Clinical and Translational Oncology.2023; 25(12): 3556. CrossRef
The Feasibility, Acceptability, and Effectiveness of Electronic Patient-Reported Outcome Symptom Monitoring for Immune Checkpoint Inhibitor Toxicities: A Systematic Review Julia Lai-Kwon, Jordan E. Cohen, Karolina Lisy, Claudia Rutherford, Afaf Girgis, Ethan Basch, Michael Jefford JCO Clinical Cancer Informatics.2023;[Epub] CrossRef
Elevated eosinophils proportion as predictor of immune‐related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma Yoshihiko Tasaki, Shuzo Hamamoto, Yosuke Sugiyama, Nami Tomiyama, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Nayuka Matsuyama, Yasuhito Sue, Yoshihisa Mimura, Hiroki Kubota, Yusuke Noda, Maria Aoki, Yoshinobu Moritoki, Satoshi Nozaki, Satoshi Kurokawa, At International Journal of Urology.2023; 30(10): 866. CrossRef
Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy Shu-Jung Hsu, Yen-Cheng Chao, Xia-Hui Lin, Hua-Hua Liu, Yang Zhang, Wei-Feng Hong, Mao-Pei Chen, Xin Xu, Lan Zhang, Zheng-Gang Ren, Shi-Suo Du, Rong-Xin Chen Clinical and Experimental Immunology.2023; 212(3): 239. CrossRef
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401 Reinhard Dummer, Pippa Corrie, Ralf Gutzmer, Tarek M. Meniawy, Michele Del Vecchio, Céleste Lebbé, Michele Guida, Caroline Dutriaux, Brigitte Dreno, Nicolas Meyer, Pier Francesco Ferrucci, Stéphane Dalle, Muhammad Adnan Khattak, Jean-Jacques Grob, Karen B Journal of Clinical Oncology.2023; 41(23): 3917. CrossRef
Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between Hyo Sook Han, Praveen Vikas, Ricardo L.B. Costa, Nusrat Jahan, Ammanuel Taye, Erica M. Stringer-Reasor American Society of Clinical Oncology Educational Book.2023;[Epub] CrossRef
An updated review of gastrointestinal toxicity induced by PD-1 inhibitors: from mechanisms to management Yiyu Cheng, Fangmei Ling, Junrong Li, Yidong Chen, Mingyang Xu, Shuang Li, Liangru Zhu Frontiers in Immunology.2023;[Epub] CrossRef
Postmarketing surveillance of nivolumab plus ipilimumab combination therapy in Japanese patients with unresectable malignant melanoma Naoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara, Tetsuya Tsuchida, Ai Yoshida, Takako Yamada, Akira Komoto The Journal of Dermatology.2023; 50(9): 1108. CrossRef
Real‐world evidence of incidence and outcomes of aplastic anaemia following administration of immune checkpoint inhibitors Srilatha Dasari, William Tse, Jiasheng Wang British Journal of Haematology.2023; 202(6): 1205. CrossRef
Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors André Manuel da Silva Lopes, Sara Colomer-Lahiguera, Célia Darnac, Stellio Giacomini, Sébastien Bugeia, Garance Gutknecht, Gilliosa Spurrier-Bernard, Veronica Aedo-Lopez, Nuria Mederos, Sofiya Latifyan, Alfredo Addedo, Olivier Michielin, Manuela Eicher Supportive Care in Cancer.2023;[Epub] CrossRef
CD4 T cells and toxicity from immune checkpoint blockade Noah Earland, Wubing Zhang, Abul Usmani, Aishwarya Nene, Antonella Bacchiocchi, David Y. Chen, Mario Sznol, Ruth Halaban, Aadel A. Chaudhuri, Aaron M. Newman Immunological Reviews.2023; 318(1): 96. CrossRef
Anti‑PD1 therapy‑associated distal renal tubular acidosis: A case report Xuejia Qiu, Bingnan Ren, Lingzhi Fang, Zhanjun Dong Experimental and Therapeutic Medicine.2023;[Epub] CrossRef
Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review Minoru Kato, Junji Uchida International Journal of Urology.2023; 30(12): 1068. CrossRef
Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab Manuel A. Baarslag, Joosje H. Heimovaara, Jessica S.W. Borgers, Koen J. van Aerde, Hans J.P.M. Koenen, Ruben L. Smeets, Pauline L.M. Buitelaar, Dick Pluim, Shoko Vos, Stefanie S.V. Henriet, Jan Willem B. de Groot, Martine van Grotel, Hilde Rosing, Jos H. New England Journal of Medicine.2023; 389(19): 1790. CrossRef
Incidence and Timing of Immune-Related Adverse Events in Immune-Checkpoint Inhibitor-Treated Patients: A Retrospective Observational Study Kou Masaki, Motoyasu Miyazaki, Hideki Kakimoto, Yuma Fukiage, Haruka Fukue, Akio Nakashima, Osamu Imakyure Journal of Clinical Medicine.2023; 12(24): 7564. CrossRef
Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview Priyatharcini Kejamurthy, K. T. Ramya Devi Medical Oncology.2023;[Epub] CrossRef
Imaging of Cancer Immunotherapy: Response Assessment Methods, Atypical Response Patterns, and Immune-Related Adverse Events, From theAJRSpecial Series on Imaging of Inflammation Sara Sheikhbahaei, Charles V. Marcus, Mohammad S. Sadaghiani, Steven P. Rowe, Martin G. Pomper, Lilja B. Solnes American Journal of Roentgenology.2022; 218(6): 940. CrossRef
Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation Cody J. Peer, Brian L. Heiss, Daniel A. Goldstein, Jennifer C. Goodell, William D. Figg, Mark J. Ratain The Journal of Clinical Pharmacology.2022; 62(4): 532. CrossRef
T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma Alexander X. Lozano, Aadel A. Chaudhuri, Aishwarya Nene, Antonietta Bacchiocchi, Noah Earland, Matthew D. Vesely, Abul Usmani, Brandon E. Turner, Chloé B. Steen, Bogdan A. Luca, Ti Badri, Gunsagar S. Gulati, Milad R. Vahid, Farnaz Khameneh, Peter K. Harri Nature Medicine.2022; 28(2): 353. CrossRef
Guarantee‐time bias in studies on the relationship between immune‐related adverse events and antitumor activity Ka Man Cheung, Therese Yue Man Tsui, James Chung Hang Chow Cancer.2022; 128(13): 2549. CrossRef
CD21lo B Cells Could Be a Potential Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma Kenichi Nishimura, Tatsuya Konishi, Toshiki Ochi, Ryuta Watanabe, Terutaka Noda, Tetsuya Fukumoto, Noriyoshi Miura, Yuki Miyauchi, Tadahiko Kikugawa, Katsuto Takenaka, Takashi Saika Journal of Personalized Medicine.2022; 12(6): 888. CrossRef
A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer Eo Jin Kim, Yong-Hee Cho, Dong Ha Kim, Dae-Hyun Ko, Eun-Ju Do, Sang-Yeob Kim, Yong Man Kim, Jae Seob Jung, Yoonmi Kang, Wonjun Ji, Myeong Geun Choi, Jae Cheol Lee, Jin Kyung Rho, Chang-Min Choi Cancer Research and Treatment.2022; 54(4): 1005. CrossRef
Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences Ana Cardeña-Gutiérrez, Mónica López Barahona Frontiers in Medicine.2022;[Epub] CrossRef
Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy Afaf Abed, Ngie Law, Leslie Calapre, Johnny Lo, Vikas Bhat, Samantha Bowyer, Michael Millward, Elin S. Gray European Journal of Cancer.2022; 172: 98. CrossRef
Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma Dirk Tomsitz, Max Schlaak, Sarah Zierold, Giulia Pesch, Thomas U. Schulz, Genoveva Müller, Christine Zecha, Lars E. French, Lucie Heinzerling Cancers.2022; 14(13): 3282. CrossRef
Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer Ben-Max de Ruiter, Jons W. van Hattum, Djoeri Lipman, Theo M. de Reijke, R. Jeroen A. van Moorselaar, Erik J. van Gennep, A.H. Maartje Piet, Mila Donker, Tom van der Hulle, Jens Voortman, Jorg R. Oddens, Maarten C.C.M. Hulshof, Adriaan D. Bins European Urology.2022; 82(5): 518. CrossRef
Adverse Renal Effects of Anticancer Immunotherapy: A Review Maciej Borówka, Stanisław Łącki-Zynzeling, Michał Nicze, Sylwia Kozak, Jerzy Chudek Cancers.2022; 14(17): 4086. CrossRef
Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence Nari Kim, Eun Sung Lee, Sang Eun Won, Mihyun Yang, Amy Junghyun Lee, Youngbin Shin, Yousun Ko, Junhee Pyo, Hyo Jung Park, Kyung Won Kim Korean Journal of Radiology.2022; 23(11): 1089. CrossRef
Use of PD-1 inhibitors in patients with end-stage renal disease: safety and clinical outcomes from real-world data Jiasheng Wang, Srilatha Dasari, Dina Elantably, Akram Alkrekshi, Yeseong David Kim Acta Oncologica.2022; 61(9): 1157. CrossRef
Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma Chan Kim, Hannah Yang, Ilhwan Kim, Beodeul Kang, Hyeyeong Kim, Hyunho Kim, Won Suk Lee, Sanghoon Jung, Ho Yeong Lim, Jaekyung Cheon, Hong Jae Chon JAMA Oncology.2022; 8(12): 1825. CrossRef
Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity Ik Shin Chin, Aman Khan, Anna Olsson-Brown, Sophie Papa, Gary Middleton, Claire Palles npj Genomic Medicine.2022;[Epub] CrossRef
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors Deniz Can Guven, Deniz Aral Ozbek, Taha Koray Sahin, Gozde Kavgaci, Melek Seren Aksun, Enes Erul, Hasan Cagri Yildirim, Elvin Chalabiyev, Cebrayil Cebroyilov, Tolga Yildirim, Omer Dizdar, Sercan Aksoy, Suayib Yalcin, Saadettin Kilickap, Mustafa Erman, Mus Anti-Cancer Drugs.2022;[Epub] CrossRef
Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer Lance L. Munn, Triantafyllos Stylianopoulos, Natalie K. Jain, C. Corey Hardin, Melin J. Khandekar, Rakesh K. Jain Clinical Cancer Research.2021; 27(10): 2706. CrossRef
Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma Jonathan T. Hunt, Laura M. Chambers, Meng Yao, Amy Joehlin-Price, Robert Debernardo, Peter G. Rose Gynecologic Oncology Reports.2021; 37: 100840. CrossRef
Blocking antibody-mediated phosphatidylserine enhances cancer immunotherapy Jie Zhang, Zhujiang Dai, Cheng Yan, Daorong Wang, Dong Tang Journal of Cancer Research and Clinical Oncology.2021; 147(12): 3639. CrossRef
Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC Jay M. Lee, Anthony W. Kim, Tomasz Marjanski, Pierre-Emmanuel Falcoz, Masahiro Tsuboi, Yi-Long Wu, Shawn W. Sun, Barbara J. Gitlitz JTO Clinical and Research Reports.2021; 2(10): 100221. CrossRef
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update Bryan J. Schneider, Jarushka Naidoo, Bianca D. Santomasso, Christina Lacchetti, Sherry Adkins, Milan Anadkat, Michael B. Atkins, Kelly J. Brassil, Jeffrey M. Caterino, Ian Chau, Marianne J. Davies, Marc S. Ernstoff, Leslie Fecher, Monalisa Ghosh, Ishmael Journal of Clinical Oncology.2021; 39(36): 4073. CrossRef
Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy Pan Shen, Xuan Deng, Zhishuo Hu, Zhe Chen, Yao Huang, Ke Wang, Kai Qin, Ying Huang, Xin Ba, Jiahui Yan, Liang Han, Shenghao Tu Frontiers in Medicine.2021;[Epub] CrossRef
Purpose
The purpose of this study was to investigate the effect of neutropenia during the first cycle of induction chemotherapy (IC-1) on survival in locoregionally advanced nasopharyngeal carcinoma (LANPC).
Materials and Methods
Eligible patients (n=545) with LANPC receiving IC+concurrent chemoradiotherapy were included. Based on nadir neutrophil afterIC-1, all patientswere categorized into three groups: no/grade 1-2/grade 3-4 neutropenia. Five-year overall survival (OS) and disease-free survival (DFS) were compared between groups and subgroups stratified by IC regimen. We also explored the occurrence of IC-1–induced myelosuppression events and the minimal value of post-treatment neutrophil-to-lymphocyte ratio (post-NLRmin). Univariate/multivariate analyses were performed to investigate the effect of IC-1–induced neutropenia, timing of neutropenia, number of myelosuppression events, and high post-NLRmin on OS/DFS.
Results
Grade 1-2/grade 3-4 neutropeniawere associatedwith poorer OS/DFS than no neutropenia (all p < 0.05); OS/DFS were not significantly different between patients experiencing grade 1-2 vs. 3-4 neutropenia. Neutropenia had no significant effect on OS/DFS in patients receiving docetaxel–cisplatin–5-fluorouracil (TPF). Grade 1-2 (grade 3-4) neutropenia negatively influenced OS/DFS in patients receiving cisplatin–5-fluorouracil (PF) (PF and docetaxel–cisplatin [TP]; all p < 0.05). Neutropenia, two/three myelosuppression events, and high post-NLRmin (≥ 1.33) was most frequent on days 5-10, second and third week of IC-1, respectively. After adjustment for covariates, IC-1–induced neutropenia, two/three myelosuppression events, and post-NLRmin ≥ 1.33were validated as negative predictors of OS/DFS (all p < 0.05); timing of neutropenia had no significant effect.
Conclusion
Occurrence of neutropenia, number of myelosuppression events, and high post-NLRmin during PF/TP IC-1 have prognostic value for poor survival in LANPC.
Citations
Citations to this article as recorded by
Prospective clinical study of the efficacy and safety of different doses of PEG recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for preventing leukopenia/neutropenia caused by concurrent chemoradiotherapy for cervical cancer Tingting Yu, Yiwei Zhang, Jiawen Li, Zhuo Li, Rui Tong Holistic Integrative Oncology.2024;[Epub] CrossRef
Incidence, consequences, and predictors of serious chemotherapy‐induced thrombocytopenia in nasopharyngeal carcinoma Lu‐Lu Zhang, Xi Chen, Ying‐Ying Huang, Chi‐Xiong Liang, Meng‐Yun Qiang, Zhuo‐Chen Cai, Ze‐Jiang Zhan, Ying Deng, Jia‐Yu Zhou, Hao‐Yang Huang, Xiang Guo, Xing Lv Cancer Medicine.2023; 12(13): 14084. CrossRef
Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2023 edition) Jun Wang, Baosheng Li Precision Radiation Oncology.2023; 7(3): 150. CrossRef
Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2020 edition) Jun Wang, Baosheng Li Precision Radiation Oncology.2021; 5(1): 4. CrossRef
Prognostic value of serum uric acid and tumor response to induction chemotherapy in locally advanced nasopharyngeal carcinoma Yuanji Xu, Zijie Wu, Wangzhong Ye, Youping Xiao, Wei Zheng, Qinyan Chen, Penggang Bai, Zhizhong Lin, Chuanben Chen BMC Cancer.2021;[Epub] CrossRef
Prognostic value of post-radiotherapy neutrophil-to-lymphocyte ratio in locally advanced nasopharyngeal carcinoma Dan Ou, Xiaoshen Wang, Mingyao Wu, Fen Xue, Yujiao Li, Chaosu Hu, Xiayun He Strahlentherapie und Onkologie.2020; 196(3): 252. CrossRef
Amelioration of cyclophosphamide-induced myelosuppression during treatment to rats with breast cancer through low-intensity pulsed ultrasound Wei Wang, Dong Luo, Junlin Chen, Jinyun Chen, Yi Xia, Wenzhi Chen, Yan Wang Bioscience Reports.2020;[Epub] CrossRef